Ingevity Corporation
NGVT
$40.47
$0.180.45%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.35B | 1.41B | 1.48B | 1.55B | 1.64B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.35B | 1.41B | 1.48B | 1.55B | 1.64B |
| Cost of Revenue | 875.60M | 945.40M | 1.05B | 1.12B | 1.18B |
| Gross Profit | 474.70M | 461.00M | 432.10M | 431.20M | 461.00M |
| SG&A Expenses | 162.50M | 166.60M | 171.00M | 172.30M | 182.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 500.00K | 500.00K | 500.00K | 500.00K |
| Total Operating Expenses | 1.07B | 1.14B | 1.25B | 1.32B | 1.39B |
| Operating Income | 283.20M | 265.80M | 232.60M | 229.30M | 248.10M |
| Income Before Tax | -436.90M | -535.60M | -698.40M | -528.40M | -146.10M |
| Income Tax Expenses | -83.10M | -105.30M | -134.70M | -97.10M | -34.00M |
| Earnings from Continuing Operations | -353.80 | -430.30 | -563.70 | -431.30 | -112.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -353.80M | -430.30M | -563.70M | -431.30M | -112.10M |
| EBIT | 283.20M | 265.80M | 232.60M | 229.30M | 248.10M |
| EBITDA | 384.40M | 374.10M | 338.90M | 347.50M | 369.40M |
| EPS Basic | -9.74 | -11.84 | -15.53 | -11.88 | -3.10 |
| Normalized Basic EPS | 2.89 | 2.15 | 1.63 | 1.55 | 2.25 |
| EPS Diluted | -9.75 | -11.85 | -15.54 | -11.90 | -3.12 |
| Normalized Diluted EPS | 2.88 | 2.14 | 1.63 | 1.55 | 2.24 |
| Average Basic Shares Outstanding | 145.36M | 145.24M | 145.14M | 145.02M | 145.06M |
| Average Diluted Shares Outstanding | 145.94M | 145.54M | 145.14M | 145.19M | 145.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |